Ten cases of Stage 4 neuroblastoma diagnosed at more than a year old

NDL Digital Collections 10 References
  • AOKI,Yoshinori
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • KOH,Katsuyoshi
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • Takita,Junko
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • HORIE,Go
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • SEKI,Masafumi
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • FURUYA,Ayaka
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • IDA,Kohmei
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo
  • IGARASHI,Takashi
    Department of Pediatrics, Faculty of medicine, University of Tokyo:Department of Cell Therapy and Transplantation Medicine, University of Tokyo

Bibliographic Information

Other Title
  • 最近当科で経験した1歳以上の神経芽腫stage 4の10例

Search this article

Description

Neuroblastoma (NB) is the most common extracranial solid tumor in childhood that exhibits substantial heterogeneity. Although patients with early-stage NB are known to have good prognoses, patients with advanced-stage NB still continue to have poor prognoses despite recent developments in treatment. To get a better understanding of the prognostic factors of advanced NB, ten patients with stage 4 NB were retrospectively evaluated. All patients were followed-up on for at least 13 months, with some up to a total of 64 months, and the median range of follow-up periods was 44 months. The patients were treated with multidrug chemotherapy consisting of cyclophosphamide, vincristine, adriamycin, cisplatin and etoposide. After that, the patients underwent single or tandem hematopoietic stem cell transplantation. Two of ten patients died and two of the remaining eight patients relapsed after high-dose chemotherapy. Urinary VMA, HVA and serum NSE were normalized in five patients after three-cycle chemotherapy, and all these cases maintained complete remission without relapse. However, these tumor markers were not normalized in the other four patients during the same period, and three of them relapsed. On the other hand, of our ten patients, one case of a relapsed tumor underwent allogenic bone marrow transplantation and was in complete remission for 28 months. There fore the evaluation of urinary VMA, HVA and serum NSE after three cycles of chemotherapy would be useful to predict outcome of patients with advanced NB. In addition, a new treatment strategy is necessary for high risk cases with NB.

Journal

References(10)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top